Physician profile
Anne Smith
NPI 1255956652
$3,068.17
in general payments reported to CMS, 2019-2025
32 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $792 · 2023: $932 · 2024: $220 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.79 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $841.73 | 2021-2023 | Glassia |
| Harmony Biosciences LLC | $659.26 | 2021-2023 | Wakix |
| Astrazeneca Pharmaceuticals LP | $266.89 | 2021-2024 | Breztri, Fasenra, Wainua |
| Grifols USA, LLC | $157.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $126.55 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2022 | |
| Amgen INC. | $101.38 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.67 | 2021-2023 | Ofev, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $98.20 | 2021-2023 | |
| Mylan Specialty L.P. | $58.20 | 2022-2023 | Yupelri |
| Heartflow, INC. | $57.25 | 2024-2025 | |
| Boston Scientific Corporation | $47.59 | 2025 | Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $44.87 | 2024 | Arcalyst |
| Philips North America LLC | $40.06 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $31.60 | 2024 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $28.25 | 2025 | Nexletol |
| Abiomed | $26.45 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $24.06 | 2025 | Verquvo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.99 | 2025 | Caplyta |
| Optinose US, INC. | $19.68 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.99 | 2023 | Camzyos |
| Genzyme Corporation | $18.81 | 2023 | |
| Inspire Medical Systems, INC. | $17.59 | 2025 | Inspire |
| Pharming Healthcare, INC. | $16.54 | 2023 | Ruconest |
| Csl Behring | $16.49 | 2023 | Hizentra |
| United Therapeutics Corporation | $16.37 | 2023 | Tyvaso |
| Scpharmaceuticals INC. | $16.11 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.62 | 2023 | Dupixent |
| Electromed, INC. | $14.89 | 2024 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $14.81 | 2024 | |
| Glaxosmithkline, LLC. | $14.78 | 2023 | Trelegy Ellipta, Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.48 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.